TapewireFind a company

person · Reporting owner

Pestano Gary Anthony

Disclosed activity across 1 company

Tapewire entity
65173
SEC CIK
0001827711

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIODESIX INCBDSX · Entity 6053Chief Development OfficerFebruary 20, 2026February 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date February 20, 2026 · Filed February 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,359 Ending reported balance After 2026-02-23 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-20 · Exercise / conversion · Acquired 1,528 · Balance 10,915

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Row 2 · 2026-02-23 · Sale · Disposed 556 · Balance 10,359

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect4,582 Reported balance After 2026-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-20 · Exercise / conversion · Disposed 1,528 · Balance 4,582

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 08, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 29,633 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-000586 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 10, 2023 Filed Nov 13, 2023 21:51 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 218 $1.23 $267.18
Disclosure

SEC source: 0000905148-23-001384 · form4.xml · nonDerivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,501

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 09, 2023 Filed Nov 13, 2023 21:51 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 217 $1.27 $275.74
Disclosure

SEC source: 0000905148-23-001384 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,719

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.23 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 21:51 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,378 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-001384 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,404

Underlying: Common Stock · 1,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2023 Filed Nov 13, 2023 21:51 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,378 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-23-001384 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,936

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 10, 2023 Filed Aug 10, 2023 23:29 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 786 $1.27 $995.78
Disclosure

SEC source: 0000905148-23-000667 · form4.xml · nonDerivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,558

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 23:29 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 787 $1.39 $1,092.59
Disclosure

SEC source: 0000905148-23-000667 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,344

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:29 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,675 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-000667 · form4.xml · derivative · entry 5

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:29 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,379 $0.00 $0.00
Disclosure

SEC source: 0000905148-23-000667 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,782

Underlying: Common Stock · 1,379 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2023 Filed Aug 10, 2023 23:29 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,054 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-23-000667 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
August 03, 2023 Filed Aug 7, 2023 21:32 UTC BIODESIX INC BDSX · Entity 6053 GrantCommon Stock 617 $1.62 $999.54
Disclosure

SEC source: 0000905148-23-000627 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,077

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 6,497 Not disclosed Strike: $1.20 Not disclosed
Disclosure

SEC source: 0000905148-23-000512 · form4.xml · derivative · entry 6

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,497

Underlying: Common Stock · 6,497 shares

Expires 2033-07-23

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F5 · kind: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F5 · price: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled.

F6 · derivative.exercise_date: This Replacement Option vests as follows: 3,846 shares of Common Stock underlying this Replacement Option vest on August 1, 2024, and the remaining 2,651 shares of Common Stock underlying this Replacement Option vest in 31 successive, equal monthly installments beginning on August 1, 2024.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:16 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 1,000 Not disclosed Strike: $13.72 Not disclosed
Disclosure

SEC source: 0000905148-23-000512 · form4.xml · derivative · entry 5

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,000 shares

Expires 2031-06-28

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F5 · kind: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F5 · price: The Reporting Person elected to participate in the Tender Offer and received 313 Replacement Options with an exercise price of $1.20 per share in exchange for 1,000 Surrendered Options with an exercise price of $13.72 per share, after which the Surrendered Options were cancelled.

F2 · derivative.exercise_date: This option was fully vested as of the grant date.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:16 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 5,155 Not disclosed Strike: $20.67 Not disclosed
Disclosure

SEC source: 0000905148-23-000512 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,155 shares

Expires 2031-02-22

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F2 · derivative.exercise_date: This option was fully vested as of the grant date.

Read SEC document
July 24, 2023 Filed Jul 26, 2023 22:16 UTC BIODESIX INC BDSX · Entity 6053 Disposition to issuerStock Options (Right to buy) · Derivative 25,134 Not disclosed Strike: $20.67 Not disclosed
Disclosure

SEC source: 0000905148-23-000512 · form4.xml · derivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,134 shares

Expires 2031-02-22

F3 · kind: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · kind: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F3 · price: On June 23, 2023, the Issuer made an offer (the "Tender Offer") to certain employees to exchange some or all of their outstanding options with an exercise price greater than $10.00 per share (such options properly tendered for exchange, "Surrendered Options") for new options with terms determined in accordance with the terms of the Tender Offer ("Replacement Options"). The Tender Offer closed on July 24, 2023, and the Issuer's board of directors approved the exchange of Surrendered Options for Replacement Options on July 24, 2023.

F4 · price: The Reporting Person elected to participate in the Tender Offer and received 6,184 Replacement Options with an exercise price of $1.20 per share in exchange for 30,289 Surrendered Options with an exercise price of $20.67 per share, after which the Surrendered Options were cancelled.

F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.

Read SEC document
May 10, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 426 $1.58 $671.42
Disclosure

SEC source: 0001140361-23-023965 · form4.xml · nonDerivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,460

F2 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.5332 to $1.615, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,101 $1.57 $1,724.61
Disclosure

SEC source: 0001140361-23-023965 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,886

F2 · kind: These shares of the Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,676 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023965 · form4.xml · derivative · entry 5

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,675

Underlying: Common Stock · 3,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,378 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-023965 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,161

Underlying: Common Stock · 1,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2023 Filed May 11, 2023 00:16 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,054 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-23-023965 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 8,614 $0.00 Strike: $2.00 $0.00
Disclosure

SEC source: 0001140361-23-010027 · form4.xml · derivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,614

Underlying: Common Stock · 8,614 shares

Expires 2033-02-28

F1 · derivative.exercise_date: This option vested in full on March 1, 2023. Under the Issuer's 2022 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2022 in the form of a fully-vested option.

Read SEC document
February 09, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,852 $1.80 $3,331.93
Disclosure

SEC source: 0001140361-23-006077 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,933

F2 · kind: These shares of Issuer's common stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,675 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006077 · form4.xml · derivative · entry 5

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,351

Underlying: Common Stock · 3,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F6 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,378 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006077 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,539

Underlying: Common Stock · 1,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 113,021 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-006077 · form4.xml · derivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,021

Underlying: Common Stock · 113,021 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

F4 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2023 Filed Feb 10, 2023 23:40 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,053 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-23-006077 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,785

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Issuer's common stock.

Read SEC document
November 10, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 698 $1.02 $710.22
Disclosure

SEC source: 0001140361-22-041078 · form4.xml · nonDerivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,732

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F6 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 09, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 882 $1.04 $918.87
Disclosure

SEC source: 0001140361-22-041078 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,430

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,676 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-041078 · form4.xml · derivative · entry 5

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,026

Underlying: Common Stock · 3,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,378 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-041078 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,917

Underlying: Common Stock · 1,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2022 Filed Nov 11, 2022 02:02 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,054 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-041078 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
August 09, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,549 $2.53 $3,916.18
Disclosure

SEC source: 0001140361-22-029134 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,258

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $2.38 to $2.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,675 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029134 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,702

Underlying: Common Stock · 3,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,379 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-029134 · form4.xml · derivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,295

Underlying: Common Stock · 1,379 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2022 Filed Aug 10, 2022 22:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,054 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-029134 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,807

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
May 10, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 1,467 $1.83 $2,684.61
Disclosure

SEC source: 0001140361-22-018732 · form4.xml · nonDerivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,753

F4 · kind: These Shares were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 3,676 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-018732 · form4.xml · derivative · entry 4

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,377

Underlying: Common Stock · 3,676 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,378 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-018732 · form4.xml · derivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,674

Underlying: Common Stock · 1,378 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2022 Filed May 12, 2022 01:41 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 5,054 Not disclosed Not disclosed
Disclosure

SEC source: 0001140361-22-018732 · form4.xml · nonDerivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").

Read SEC document
March 10, 2022 Filed Mar 14, 2022 21:47 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 5,845 $0.00 Strike: $2.29 $0.00
Disclosure

SEC source: 0001567619-22-006915 · doc1.xml · derivative · entry 3

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,845

Underlying: Common Stock · 5,845 shares

Expires 2032-03-09

Read SEC document
March 10, 2022 Filed Mar 14, 2022 21:47 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 5,615 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001567619-22-006915 · doc1.xml · derivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,230

Underlying: Common Stock · 5,615 shares

Expires 2029-03-21

F1 · shares: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option.

F3 · shares: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 5,615 shares underlying the option.

F1 · derivative.exercise_date: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option.

F3 · derivative.exercise_date: On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 5,615 shares underlying the option.

Read SEC document
February 08, 2022 Filed Feb 11, 2022 00:09 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 22,053 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-004587 · form4.xml · derivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,053

Underlying: Common Stock · 22,053 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F3 · derivative.exercise_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F3 · derivative.expiration_date: These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2022 Filed Feb 11, 2022 00:09 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 22,052 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-004587 · form4.xml · derivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,052

Underlying: Common Stock · 22,052 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 22:27 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 1,000 $0.00 Strike: $13.72 $0.00
Disclosure

SEC source: 0000905148-21-000542 · form4.xml · derivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires 2031-06-28

F1 · derivative.exercise_date: This option vests in a series of sixty (60) successive equal monthly installments measured from March 12, 2021, subject to the reporting person's continuous service through the applicable vesting date.

Read SEC document
February 23, 2021 Filed Mar 14, 2022 21:47 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 5,615 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001567619-22-006915 · doc1.xml · derivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,615

Underlying: Common Stock · 5,615 shares

Expires 2029-03-21

F1 · shares: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option.

F2 · shares: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 5,615 shares underlying the option.

F1 · derivative.exercise_date: On March 22, 2019, the Reporting Person was granted an option to purchase 16,845 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,615 shares underlying the option.

F2 · derivative.exercise_date: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 5,615 shares underlying the option.

Read SEC document
February 23, 2021 Filed Jul 26, 2023 22:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 5,155 $0.00 Strike: $20.67 $0.00
Disclosure

SEC source: 0000905148-23-000512 · form4.xml · derivative · entry 2

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,155

Underlying: Common Stock · 5,155 shares

Expires 2031-02-22

F2 · derivative.exercise_date: This option was fully vested as of the grant date.

Read SEC document
February 23, 2021 Filed Jul 26, 2023 22:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 25,134 $0.00 Strike: $20.67 $0.00
Disclosure

SEC source: 0000905148-23-000512 · form4.xml · derivative · entry 1

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,134

Underlying: Common Stock · 25,134 shares

Expires 2031-02-22

F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021.

Read SEC document
December 18, 2020 Filed Dec 21, 2020 21:15 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to buy) · Derivative 4,327 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0001140361-20-029017 · form4.xml · derivative · entry 18

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,258

Underlying: Common Stock · 4,327 shares

Expires 2030-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2020.

Read SEC document
December 18, 2020 Filed Dec 21, 2020 21:15 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to buy) · Derivative 10,984 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0001140361-20-029017 · form4.xml · derivative · entry 17

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,655

Underlying: Common Stock · 10,984 shares

Expires 2028-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option vests twenty-one sixtieths (21/60ths) on October 1, 2020, the remaining balance vests in 39 successive, equal monthly installments measured from October 1, 2020.

Read SEC document
December 18, 2020 Filed Dec 21, 2020 21:15 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionStock Options (Right to buy) · Derivative 12,285 $0.00 Strike: $0.42 $0.00
Disclosure

SEC source: 0001140361-20-029017 · form4.xml · derivative · entry 16

Pestano Gary Anthony · CIK 0001827711 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,773

Underlying: Common Stock · 12,285 shares

Expires 2028-04-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2018.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.